Literature DB >> 19583455

Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Claudine M Baldwin1, Susan J Keam.   

Abstract

Rabeprazole (Aciphex, Alfence, Pariet) is a proton pump inhibitor (PPI) used for the treatment of adults with conditions requiring a reduction of gastric acid secretion such as erosive or ulcerative gastro-oesophageal reflux disease (GORD), non-erosive reflux disease (NERD), duodenal and gastric ulcers, and pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES). It is also used as part of combination therapy for the eradication of Helicobacter pylori, a pathogen frequently implicated in the development of gastric and duodenal ulcers. Rabeprazole has a well established efficacy and safety profile in the treatment of gastric acid-related diseases. Rabeprazole is a useful, well tolerated and cost-effective option for the treatment of GORD, NERD, peptic ulcer and other gastric acid-related diseases (including ZES), and provides an appropriate alternative to other currently available PPIs, with the added benefits of having a consistent efficacy profile and low drug interaction potential due to its predominantly nonenzymatic metabolism.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19583455     DOI： 10.2165/00003495-200969100-00007

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  83 in total

1.  Gastro-oesophageal reflux disease in adults: Guidelines for clinicians.

Authors:  Peter Katelaris; Richard Holloway; Nicholas Talley; David Gotley; Steven Williams; John Dent
Journal:  J Gastroenterol Hepatol       Date:  2002-08       Impact factor: 4.029

2.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 3.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

4.  Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.

Authors:  C P Dekkers; J A Beker; B Thjodleifsson; A Gabryelewicz; N E Bell; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

5.  Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.

Authors:  Ken Ariizumi; Shuichi Ohara; Tomoyuki Koike; Yoshifumi Inomata; Katsunori Iijima; Hitoshi Sekine; Mitsunori Noguchi; Koichi Sugiyama; Yoshiki Eda; Shoichi Kayaba; Msashi Kawamura; Tooru Shimosegawa
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

6.  "Best practice' for Helicobacter pylori eradication in the primary care setting.

Authors:  V Walshe; C O'Morain; K Bennett; P W N Keeling; M Barry
Journal:  Ir Med J       Date:  2006-01

Review 7.  Rabeprazole.

Authors:  A Prakash; D Faulds
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

8.  Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.

Authors:  M Vergara; M Vallve; J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

9.  Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.

Authors:  P Bytzer; A Blum; D De Herdt; D Dubois
Journal:  Aliment Pharmacol Ther       Date:  2004-07-15       Impact factor: 8.171

10.  Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects.

Authors:  Steve Warrington; Kathy Baisley; Kate Dunn; Malcolm Boyce; Anna Morocutti
Journal:  Eur J Clin Pharmacol       Date:  2006-07-19       Impact factor: 2.953
View more
  8 in total

1.  Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.

Authors:  Caroline T Nguyen; Michael I MacEntee; Barbara Mintzes; Thomas L Perry
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

Review 2.  Pharmacotherapy of Zollinger-Ellison syndrome.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2013-01-30       Impact factor: 3.889

3.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.

Authors:  Robert T Jensen; Guillaume Cadiot; Maria L Brandi; Wouter W de Herder; Gregory Kaltsas; Paul Komminoth; Jean-Yves Scoazec; Ramon Salazar; Alain Sauvanet; Reza Kianmanesh
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

Review 4.  Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.

Authors:  Nihal El Rouby; John J Lima; Julie A Johnson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-04-12       Impact factor: 4.481

5.  Comparison of Outcomes in Patients with Obesity Between Two Administration Routes of Omeprazole After Laparoscopic Sleeve Gastrectomy: An Open-Label Randomized Clinical Trial.

Authors:  Qin Tan; Yanding Gao; Pin Zhang; Yan Huo; Yihan Lu; Weifeng Huang
Journal:  Drug Des Devel Ther       Date:  2021-04-15       Impact factor: 4.162

6.  An open-label, non-comparative, non-interventional, multi-center, post-authorization safety study on the administration of rabeprazole to adults with gastro-esophageal reflux disease.

Authors:  Irini Zouboulis-Vafiadis; Emmanuel Paraskevas; Dimitrios Tzourmakliotis; Maria Hatzikyriakou; Angeliki Mestoussi; Vassilios Vasdekis; Nikolaos Katsilabros; Athanasios Arhimandritis; Alexandra Papadokostopoulou
Journal:  Ann Gastroenterol       Date:  2014

7.  Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur.

Authors:  Xinsheng Teh; Yalda Khosravi; Woon Ching Lee; Alex Hwong Ruey Leow; Mun Fai Loke; Jamuna Vadivelu; Khean Lee Goh
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

8.  Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.

Authors:  Xu Shu; Zhenhua Zhu; Yu Fu; Zhenyu Zhang; Jiangbin Wang; Xing Li; Shuixiang He; Huizhen Fan; Side Liu; Guoxin Zhang; Jianhua Tang; Caibin Huang; Qin Du; Xiaoyan Wang; Baohong Xu; Yiqi Du; Qikui Chen; Bangmao Wang; Ying Chen; Xianghui Duan; Yong Xie; Lijuan Huo; Xiaohua Hou; Nonghua Lu
Journal:  Front Med (Lausanne)       Date:  2021-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.